POET Trades Below Cash. The Business Is Priced at $0

Thursday afternoon POET Technologies (POET) printed $4.22. Take that times the 173.0 million shares on the last filed share count and you get a market cap of about $730 million. Now open the same filing. Cash and short-term investments at June 30: $796.3 million. Read that again. The company is worth less than the money in its own bank accounts. Not the business plus the cash. Less than the cash.

We've been writing this story down the ladder. At $5.38 the market paid 98 cents a share for the business. At $4.97 it paid 57 cents. At $4.22 it's paying less than nothing, minus 18 cents a share. Here's the arithmetic, straight from the filed statements, and here's what's in the pile the market just marked to zero.

What the tape did

This wasn't a POET story. It was a sector story & POET was along for the ride. The Democrats swept the House and Senate on Tuesday, and by Wednesday the chip tape had decided that meant data-center regulation. Rep. Yassamin Ansari of Arizona posted that a pause on advanced AI should be a day-one priority. A Goldman Sachs note put about 45% of planned US data-center capacity in states weighing tougher rules. Qualcomm missed on handset chips. Advanced Micro Devices (AMD) beat, guided above the Street, and still got sold. That last one is the tell. When good numbers get sold, nobody's reading numbers.

So the whole basket went out the window together. $AAOI fell 13%. $AMD 12%. $LITE 11%. Micron Technology (MU), Marvell Technology (MRVL) and $COHR all lost about 9%. iShares Semiconductor ETF (SOXX) lost 7%, and $POET gave back 14% to $4.22. A dozen companies, one trade. The money rotated into blue chips and the hyperscalers, the landlords of AI, and the suppliers paid for it.

Not everyone on the Street showed up for the funeral. Jefferies reiterated its Buy on $AMD this week with a $650 target, pointing to server CPU growth and widening AI GPU deployments. Its semis desk expects chip-equipment spending to keep climbing through 2028 and carries Buys on $NVDA, $AMAT and $LRCX. Jefferies' global strategist, Chris Wood, is the house bear on hyperscaler capex. Even he tells clients the careful way to play it is picks and shovels. POET makes shovels.

The arithmetic is jaw dropping

Everything below comes from POET's June 30 financial statements, filed with the SEC in August. No models. No estimates. Just the balance sheet and a calculator.

Cash and short-term investments: $796.3 million. Shares outstanding: 173,035,169. That's $4.60 of cash per share. The stock is $4.22. So the shares trade 38 cents under the cash, before you count anything else the company owns. Market cap is about $730 million, which makes cash 109% of market cap. Enterprise value is negative. Add back the $5.8 million interest-free note owed to a former JV partner and about $2 million of leases, and EV sits around minus $58 million.

Now be harsh about it. Take every liability on the balance sheet, all $34.3 million. That includes a $22 million derivative warrant liability, an accounting entry that moves with the stock price and never costs the company a dollar. Net cash after all of it: $762 million, or $4.40 a share. Against a $4.22 stock, the business is worth minus 18 cents. Call it minus $32 million. The market will pay you $32 million to take the operating company off its hands.

And the cash line isn't even the whole asset side. There's a $30.6 million loan POET made at 6% to a company it can convert into equity. Add $3 million of Lessengers preferred stock and $15.9 million of equipment, most of it in Asia. Patents sit on the books at $576,000, which is what patents always look like on a balance sheet. Total shareholders' equity: $847.5 million, or $4.90 a share. The stock trades at 86 cents on book.

One more check, because someone will ask about dilution. Count every warrant and option that's actually in the money at $4.22, add the RSUs, add the cash those exercises would bring in, and cash per share still works out to about $4.30. That's above the stock. The claim survives the dilution math.

What's in the pile marked to zero

Start with Lumilens. On May 14 POET announced a supply agreement with an initial purchase order of $50 million for optical engines, inside a framework that could run past $500 million over five years. Lumilens got warrants on 22.9 million shares at $8.25 that vest as it pays for orders. Engineering samples are expected late this year, with a production ramp planned for 2027. POET's engines aren't in anything Lumilens ships today, and the company said so in May. That's the customer's clock, not ours. But the customer is real. Lumilens came out of stealth in August with a $700 million-plus Series C at a $5.51 billion valuation, and it placed that order while it was still a secret.

Then the rest of the engagement list from the company's September investor deck. It names 1.6T engines with Mitsubishi Electric, 1.6T and 3.2T work with NTT, and edge optics with Adtran. It counts 49 patents and 37 applications, and roughly 155 people in six countries. And it sits on six straight quarters of sequential revenue growth through June.

And it isn't only an AI story, which matters on a day the market is selling AI. POET's partnership with NTT Innovative Devices, the components arm of Japan's biggest telecom, is for a 100G bidirectional optical engine for mobile front-haul networks. Those are the fiber links that carry cell-site radio traffic back into the network. The target is four times the bandwidth efficiency of today's parts, prototypes this year and volume production in 2027. Add Adtran at the network edge and Mitsubishi Electric on 1.6T engines. Network connectivity is the business. AI data centers are its biggest customer right now, not its only one. Nobody in Congress is proposing a pause on cell towers.

The market's price for all of it, as of Thursday: zero. Less than zero.

The objective side of the ledger

Stocks can trade below cash for a long time. The market isn't wrong about the risks. It's pricing them at infinity, which is a different thing.

The risks are real. Revenue was $569,925 last quarter. The company burned about $12 million from operations in Q2, plus capex, and its own deck pencils in roughly $15 million a quarter of burn and about $60 million of 2026 capex. The June 30 cash number is four months old. The September 30 number lands with the Q3 release on Monday, Nov. 16, pre-market, with no conference call. The first call comes with the year-end results in March. Knock $30 million off for a quarter of burn and capex at the deck's run rate and net cash is still about $4.23 a share, a penny above where the stock is trading. Even after the haircut, the market is paying nothing for the business.

Two things cut the other way. The cash earns money: $4.3 million of interest and other income in Q2, more than the company booked in revenue. And there's nothing ahead of the common. No credit facilities, no bonds, no converts beyond that $5.8 million note. There are 78.7 million warrants out there at a $4.39 average strike, and the stock just fell through that number. Only about 7 million of them are in the money down here. The big blocks sit at $7.12, $8.25 and $26.25.

The Lumilens clause everyone skips matters too. Fulfillment depends on qualification and on building the capacity. That's the whole bet. The market is saying it won't happen. The filing says it's funded if it does.

What market is watching

Nov. 16 resets the floor. The September 30 cash number replaces the June 30 one, and the seventh sequential revenue quarter either prints or it doesn't.

$4.39 and $4.40 are the levels, and both sit overhead now. One is the average warrant strike. The other is net cash per share. The stock has to reclaim numbers the balance sheet already underwrites. If it can't, the seller isn't reading balance sheets, and that kind of seller eventually runs out of stock.

The sector decides the rest. This rotation ends when $AMD stops going down on good numbers. Until then, the fundamentals here are a floor, not a fuse.

Subscribe to StockAlpha.ai for our coverage of $POET and the AI photonics trade.